Shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) reached a new 52-week low on Thursday . The company traded as low as $4.46 and last traded at $4.48, with a volume of 739,610 shares traded. The stock had previously closed at $4.57.

A number of analysts recently weighed in on SGMO shares. Janney Montgomery Scott lowered shares of Sangamo BioSciences from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $15.00 to $8.00 in a research report on Thursday, August 4th. Zacks Investment Research lowered shares of Sangamo BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Wedbush reissued an “outperform” rating and issued a $30.00 price objective on shares of Sangamo BioSciences in a research report on Friday, May 6th. Cowen and Company reissued a “buy” rating on shares of Sangamo BioSciences in a research report on Wednesday. Finally, Jefferies Group reissued a “buy” rating and issued a $14.00 price objective on shares of Sangamo BioSciences in a research report on Thursday, June 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $15.58.

The company’s market cap is $313.54 million. The company has a 50-day moving average price of $5.76 and a 200 day moving average price of $6.03.

Sangamo BioSciences (NASDAQ:SGMO) last released its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.14. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.38 million. The firm’s quarterly revenue was down 56.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.17) earnings per share. On average, equities research analysts anticipate that Sangamo BioSciences Inc. will post ($1.11) EPS for the current year.

A hedge fund recently raised its stake in Sangamo BioSciences stock. Royce & Associates LLC raised its position in Sangamo BioSciences Inc. (NASDAQ:SGMO) by 47.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 312,100 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the period. Royce & Associates LLC owned about 0.45% of Sangamo BioSciences worth $2,849,000 as of its most recent SEC filing.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.